TMEDvsIBBETF Comparison
VS
T. Rowe Price Health Care ETF (TMED) and iShares Biotechnology ETF (IBB) belong to the same industry segment: US Health Care. TMED's top 3 sector exposures are Healthcare, Consumer Non-Cyclicals and Non-Corporate. In contrast, IBB's top sector exposures are Healthcare, Non-Corporate and Non-Energy Materials. Both TMED and IBB have the same Total Expense Ratio (TER) of 0.44%. TMED is up 17.46% year-to-date (YTD) with +$13M in YTD flows. IBB performs better with 22.91% YTD performance, and +$302M in YTD flows. Run a side-by-side ETF comparison of TMED and IBB below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
TMED vs IBB performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/08/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | TMED IBB | -1.44%+3.63% | +11.05%+24.21% | +17.46%+22.91% | +35.43%+46.14% | n/a+64.83% | n/a+20.96% |
| Flows | TMED IBB | +$4M+$258M | +$10M+$788M | +$13M+$302M | +$15M+$1.81B | --$580M | --$1.46B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | TMED IBB | +18.14%+24.71% | +18.39%+21.85% | n/a+21.06% | n/a+22.47% |
| Max drawdown | TMED IBB | -4.97%-6.21% | -11.09%-9.61% | n/a-24.82% | n/a-38.96% |
| Max drawdown duration | TMED IBB | 20d31d | 125d151d | n/a377d | n/a1523d |
Trading data
TMED | IBB | |
Last sale 9/10/2026 at 1:30 PM | $34.00 | $202.64 |
| Previous close 09/09/2026 | $34.39 | $205.49 |
| Consolidated volume 09/09/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
TMED
is actively managed and doesn’t replicate an indexTMED | IBB | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/10/2026 at 1:30 PM
Live
Closed
TMED | IBB | |
|---|---|---|
| Last price | $34.00 | $202.64 |
| 1D performance | -1.13% | -1.39% |
| AuM | $33.12 M | $10.50 B |
| E/R | 0.44% | 0.44% |
Characteristics
TMED | IBB | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | T. Rowe Price | iShares |
| Benchmark | - | ICE Biotechnology Index |
| N° of holdings | 97 | 240 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 11, 2025 | February 5, 2001 |
| ESG | No | No |
Advertisement
Exposure
Countries
TMED
USA
93.59%
Other
6.41%
IBB
USA
86.04%
Other
13.96%
Sectors
TMED
Healthcare
98.58%
Other
1.42%
IBB
Healthcare
99.83%
Other
0.17%
Diversification
TMED
Total weight of top 15 holdings out of 15
61.11%
IBB
Total weight of top 15 holdings out of 15
54.48%
Top 15 holdings
Data as of July 31, 2026
TMED
Eli Lilly & Co.
16.65%
UnitedHealth Group, Inc.
5.89%
Thermo Fisher Scientific, Inc.
4.44%
Alnylam Pharmaceuticals, Inc.
4.11%
Gilead Sciences, Inc.
3.76%
Danaher Corp.
3.58%
Cencora, Inc.
3.30%
Insulet Corp.
2.73%
Agilent Technologies, Inc.
2.69%
DexCom, Inc.
2.66%
Dyne Therapeutics, Inc.
2.60%
Stryker Corp.
2.49%
West Pharmaceutical Services, Inc.
2.29%
Waters Corp.
2.20%
McKesson Corp.
1.72%
IBB
Amgen, Inc.
8.42%
Vertex Pharmaceuticals, Inc.
7.87%
Gilead Sciences, Inc.
7.14%
Regeneron Pharmaceuticals, Inc.
5.84%
argenx SE
3.55%
Natera, Inc.
2.88%
Revolution Medicines, Inc.
2.87%
Illumina, Inc.
2.42%
Biogen, Inc.
2.38%
Alnylam Pharmaceuticals, Inc.
2.14%
BeOne Medicines Ltd.
2.01%
Incyte Corp.
1.91%
Insmed, Inc.
1.71%
United Therapeutics Corp.
1.69%
Moderna, Inc.
1.65%
Frequently asked questions about TMED and IBB
How have the TMED and IBB ETFs performed in 2026?
As of September 8, 2026, TMED is up 17.46% year-to-date (YTD), while IBB has returned 22.91%. That puts IBB better performer ahead so far this year.
Which ETF is attracting more investor money: TMED or IBB?
Year-to-date, the TMED ETF saw +$13M in flows, compared to +$302M for IBB.
Which ETF is more volatile: TMED or IBB?
Over the past year, TMED had a volatility of 18.39%, while IBB experienced 21.85%.
Which ETF is bigger: TMED or IBB?
As of September 8, 2026, TMED holds $33.12 M in assets under management (AUM), while IBB manages $10.50 B.
What sectors do the TMED and IBB ETFs invest in?
TMED leans toward sectors like Healthcare. Meanwhile, IBB focuses on Healthcare.
What are the top holdings of the TMED ETF and IBB ETF?
TMED top holdings include Eli Lilly & Co., UnitedHealth Group, Inc. and Thermo Fisher Scientific, Inc.. IBB holds in its top three: Amgen, Inc., Vertex Pharmaceuticals, Inc. and Gilead Sciences, Inc..
Which ETF is more diversified: TMED or IBB?
TMED holds 97 securities with 61.11% of its assets in the top 15. IBB has 241 securities and a top 15 weight of 54.48%.
Advertisement
Latest news about TMED & IBB
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
IBB
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
IBB
Investing in the Aging Population: A Look at Bonds and Pharma ETFs
March 27, 2023
IBB
Health is Wealth: A look at the Healthcare Sector
January 24, 2023
IBB
Advertisement
Biotech ETFs – Investing in Health Innovation
July 21, 2022
IBB
Biotech ETFs – Investing in Health Innovation
July 21, 2022
IBB
Advertisement
